Thu, March 1, 2018
Wed, February 28, 2018
Tue, February 27, 2018
Mon, February 26, 2018
Fri, February 23, 2018
Thu, February 22, 2018
Wed, February 21, 2018
Tue, February 20, 2018
Fri, February 16, 2018
Thu, February 15, 2018
Wed, February 14, 2018
Tue, February 13, 2018

Matthew Luchini Maintained (BLUE) at Buy with Increased Target to $222 on, Feb 22nd, 2018


//stocks-investing.news-articles.net/content/201 .. th-increased-target-to-222-on-feb-22nd-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Matthew Luchini of BMO Capital, Maintained "bluebird bio, Inc." (BLUE) at Buy with Increased Target from $215 to $222 on, Feb 22nd, 2018.

Matthew has made no other calls on BLUE in the last 4 months.



There are 9 other peers that have a rating on BLUE. Out of the 9 peers that are also analyzing BLUE, 5 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Schmidt of "Leerink Swann" Downgraded from Buy to Hold on, Thursday, January 25th, 2018
  • Mark Breidenbach of "Oppenheimer" Initiated at Hold on, Thursday, December 21st, 2017
  • Jason McCarthy of "Maxim Group" Downgraded from Strong Buy to Hold on, Wednesday, December 13th, 2017
  • Josh Schimmer of "Evercore ISI Group" Downgraded from Buy to Hold on, Monday, November 6th, 2017
  • Matthew Harrison of "Morgan Stanley" Upgraded from Sell to Hold on, Friday, November 3rd, 2017


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Biren Amin of "Jefferies" Upgraded from Hold to Strong Buy on, Monday, December 11th, 2017
  • John Newman of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $202 on, Tuesday, December 5th, 2017
  • Dane Leone of "BTIG" Upgraded from Hold to Strong Buy on, Thursday, November 2nd, 2017
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $162 on, Thursday, November 2nd, 2017

Publication Contributing Sources